Promoter Optimization and Artificial Promoters for Transcriptional Targeting in Gene Therapy

Author(s):  
Dirk M. Nettelbeck ◽  
David T. Curiel ◽  
Rolf Müller
2007 ◽  
Vol 6 (5) ◽  
pp. 679-685 ◽  
Author(s):  
Ilya V. Ulasov ◽  
Angel A. Rivera ◽  
Adam M. Sonabend ◽  
Adam M. Sonabend ◽  
Ming Wang ◽  
...  

2001 ◽  
Vol 82 (2) ◽  
pp. 229-237 ◽  
Author(s):  
E. Casado ◽  
D.M. Nettelbeck ◽  
J. Gomez-Navarro ◽  
A. Hemminki ◽  
M. Gonzalez Baron ◽  
...  

2003 ◽  
Vol 2003 (2) ◽  
pp. 110-137 ◽  
Author(s):  
Tracy Robson ◽  
David G. Hirst

Cancer gene therapy has been one of the most exciting areas of therapeutic research in the past decade. In this review, we discuss strategies to restrict transcription of transgenes to tumour cells. A range of promoters which are tissue-specific, tumour-specific, or inducible by exogenous agents are presented. Transcriptional targeting should prevent normal tissue toxicities associated with other cancer treatments, such as radiation and chemotherapy. In addition, the specificity of these strategies should provide improved targeting of metastatic tumours following systemic gene delivery. Rapid progress in the ability to specifically control transgenes will allow systemic gene delivery for cancer therapy to become a real possibility in the near future.


2008 ◽  
Vol 16 (2) ◽  
pp. 252-260 ◽  
Author(s):  
Séverine Wack ◽  
Soukaina Rejiba ◽  
Céline Parmentier ◽  
Marc Aprahamian ◽  
Amor Hajri

2008 ◽  
Vol 199 (2) ◽  
pp. 117.e1-117.e6 ◽  
Author(s):  
Essam-Eldin R. Othman ◽  
Zeng B. Zhu ◽  
David T. Curiel ◽  
Nilufar Khatoon ◽  
Hosam T. Salem ◽  
...  

Author(s):  
Carlos Lopez ◽  
James Park ◽  
Helena Mauceri ◽  
Michael Beckett ◽  
Ralph Weichselbaum ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document